Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret O’Donnell, Ndiya Ogba, Steven D. Gore et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 655
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A. Pollyea, Katie Stehman, Jessica K. Altman et al.|Journal of the National Comprehensive Cancer Network|2023Cited by 192
Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade gliomaCarl Koschmann, María G. Castro, Daniel Zamler et al.|Oncotarget|2016Cited by 82
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AMLYan Song, Sung Won Choi, John Magenau et al.|Bone Marrow Transplantation|2015Cited by 51
Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survivalGrant Chappell, Sung Won Choi, Marcus Geer et al.|Bone Marrow Transplantation|2019Cited by 22